A qualitative systematic review of coasting, a procedure to avoid ovarian hyperstimulation syndrome in IVF patients
- PMID: 12078839
- DOI: 10.1093/humupd/8.3.291
A qualitative systematic review of coasting, a procedure to avoid ovarian hyperstimulation syndrome in IVF patients
Abstract
'Coasting', a method which consists of stopping exogenous gonadotrophins and postponing HCG administration until the patient's serum estradiol (E2) level decreases, is often used to prevent ovarian hyperstimulation syndrome (OHSS). We conducted a systematic review to analyse whether there is sufficient evidence to justify the general acceptance of coasting. The studies, which involved 493 patients in 12 studies, are very heterogeneous in the characteristics and number of patients in the ovulation stimulation schemes. The study designs, control groups, selection criteria for coasting and the OHSS classifications were variable. In most studies a threshold value of E2 was used (often 3000 pg/ml) and/or the number of follicles were considered. The fertilization rates (36.7-71%) and the pregnancy rates (20-57%) were acceptable in terms of IVF results in comparison with those of other large IVF databanks. In 16% of the cycles, ascites was described and 2.5% of the patients required hospitalization. In conclusion, while coasting does not avoid totally the risk of OHSS, it decreases its incidence in high-risk patients. Many questions remain unanswered about how coasting should be managed, and we suggest that a randomized prospective multicentre study is required.
Similar articles
-
"Coasting" (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome.Cochrane Database Syst Rev. 2002;(3):CD002811. doi: 10.1002/14651858.CD002811. Cochrane Database Syst Rev. 2002. Update in: Cochrane Database Syst Rev. 2011 Feb 16;(2):CD002811. doi: 10.1002/14651858.CD002811.pub2. PMID: 12137659 Updated.
-
Individualised gonadotropin dose selection using markers of ovarian reserve for women undergoing in vitro fertilisation plus intracytoplasmic sperm injection (IVF/ICSI).Cochrane Database Syst Rev. 2018 Feb 1;2(2):CD012693. doi: 10.1002/14651858.CD012693.pub2. Cochrane Database Syst Rev. 2018. Update in: Cochrane Database Syst Rev. 2024 Jan 4;1:CD012693. doi: 10.1002/14651858.CD012693.pub3. PMID: 29388198 Free PMC article. Updated.
-
Growth hormone for in vitro fertilisation (IVF).Cochrane Database Syst Rev. 2021 Nov 22;11(11):CD000099. doi: 10.1002/14651858.CD000099.pub4. Cochrane Database Syst Rev. 2021. PMID: 34808697 Free PMC article.
-
Depot versus daily administration of gonadotrophin releasing hormone agonist protocols for pituitary desensitization in assisted reproduction cycles.Cochrane Database Syst Rev. 2005 Jan 25;(1):CD002808. doi: 10.1002/14651858.CD002808.pub2. Cochrane Database Syst Rev. 2005. Update in: Cochrane Database Syst Rev. 2013 Jan 31;(1):CD002808. doi: 10.1002/14651858.CD002808.pub3. PMID: 15674898 Updated.
-
Depot versus daily administration of gonadotrophin releasing hormone agonist protocols for pituitary desensitization in assisted reproduction cycles.Cochrane Database Syst Rev. 2002;(3):CD002808. doi: 10.1002/14651858.CD002808. Cochrane Database Syst Rev. 2002. Update in: Cochrane Database Syst Rev. 2005 Jan 25;(1):CD002808. doi: 10.1002/14651858.CD002808.pub2. PMID: 12137658 Updated.
Cited by
-
Can steroidal ovarian suppression during the luteal phase after oocyte retrieval reduce the risk of severe OHSS?J Ovarian Res. 2015 Sep 23;8:63. doi: 10.1186/s13048-015-0190-y. J Ovarian Res. 2015. PMID: 26400057 Free PMC article.
-
Prediction of ovarian hyperstimulation syndrome in coasted patients in an IVF/ICSI program.J Hum Reprod Sci. 2012 Jan;5(1):32-6. doi: 10.4103/0974-1208.97795. J Hum Reprod Sci. 2012. PMID: 22870012 Free PMC article.
-
Pharmacologic Interventions in Preventing Ovarian Hyperstimulation Syndrome: A Systematic Review and Network Meta-Analysis.Sci Rep. 2016 Jan 11;6:19093. doi: 10.1038/srep19093. Sci Rep. 2016. PMID: 26752241 Free PMC article.
-
Ovarian Hyperstimulation Syndrome (OHSS): A Narrative Review and Legal Implications.J Pers Med. 2024 Aug 28;14(9):915. doi: 10.3390/jpm14090915. J Pers Med. 2024. PMID: 39338169 Free PMC article. Review.
-
Comparison of albumin and cabergoline in the prevention of ovarian hyperstimulation syndrome: A clinical trial study.Iran J Reprod Med. 2013 Oct;11(10):837-42. Iran J Reprod Med. 2013. PMID: 24639705 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources